248 related articles for article (PubMed ID: 27079836)
1. Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension.
Mergia E; Stegbauer J
Curr Hypertens Rep; 2016 Apr; 18(5):39. PubMed ID: 27079836
[TBL] [Abstract][Full Text] [Related]
2. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes.
Castro LR; Schittl J; Fischmeister R
Circ Res; 2010 Nov; 107(10):1232-40. PubMed ID: 20847310
[TBL] [Abstract][Full Text] [Related]
3. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
4. Cyclic GMP-dependent signaling in cardiac myocytes.
Takimoto E
Circ J; 2012; 76(8):1819-25. PubMed ID: 22785374
[TBL] [Abstract][Full Text] [Related]
5. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
Kopra K; Sharina I; Martin E; Härmä H
Sci Rep; 2020 Oct; 10(1):17469. PubMed ID: 33060787
[TBL] [Abstract][Full Text] [Related]
6. In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation.
Mullershausen F; Russwurm M; Koesling D; Friebe A
Mol Biol Cell; 2004 Sep; 15(9):4023-30. PubMed ID: 15240816
[TBL] [Abstract][Full Text] [Related]
7. Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer.
Di Iorio P; Ronci M; Giuliani P; Caciagli F; Ciccarelli R; Caruso V; Beggiato S; Zuccarini M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008687
[TBL] [Abstract][Full Text] [Related]
8. Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation.
Ni XP; Safai M; Gardner DG; Humphreys MH
Kidney Int; 2001 Apr; 59(4):1264-73. PubMed ID: 11260387
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 2 and the homeostasis of cyclic GMP in living thalamic neurons.
Hepp R; Tricoire L; Hu E; Gervasi N; Paupardin-Tritsch D; Lambolez B; Vincent P
J Neurochem; 2007 Sep; 102(6):1875-1886. PubMed ID: 17561940
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension.
Stegbauer J; Friedrich S; Potthoff SA; Broekmans K; Cortese-Krott MM; Quack I; Rump LC; Koesling D; Mergia E
PLoS One; 2013; 8(11):e80674. PubMed ID: 24260450
[TBL] [Abstract][Full Text] [Related]
11. PDE1 or PDE5 inhibition augments NO-dependent hypoxic constriction of porcine coronary artery via elevating inosine 3',5'-cyclic monophosphate level.
Nan Y; Zeng X; Jin Z; Li N; Chen Z; Chen J; Wang D; Wang Y; Lin Z; Ying L
J Cell Mol Med; 2020 Dec; 24(24):14514-14524. PubMed ID: 33169529
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide-evoked transient kinetics of cyclic GMP in vascular smooth muscle cells.
Cawley SM; Sawyer CL; Brunelle KF; van der Vliet A; Dostmann WR
Cell Signal; 2007 May; 19(5):1023-33. PubMed ID: 17207606
[TBL] [Abstract][Full Text] [Related]
13. Cyclic GMP in Vascular Relaxation: Export Is of Similar Importance as Degradation.
Krawutschke C; Koesling D; Russwurm M
Arterioscler Thromb Vasc Biol; 2015 Sep; 35(9):2011-9. PubMed ID: 26205960
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II-mediated hypertension impairs nitric oxide-induced NKCC2 inhibition in thick ascending limbs.
Ramseyer VD; Ortiz PA; Carretero OA; Garvin JL
Am J Physiol Renal Physiol; 2016 Apr; 310(8):F748-F754. PubMed ID: 26887831
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
16. Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications.
Kreisel W; Lazaro A; Trebicka J; Grosse Perdekamp M; Schmitt-Graeff A; Deibert P
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638713
[TBL] [Abstract][Full Text] [Related]
17. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases.
Dupont LL; Glynos C; Bracke KR; Brouckaert P; Brusselle GG
Pulm Pharmacol Ther; 2014 Oct; 29(1):1-6. PubMed ID: 25043200
[TBL] [Abstract][Full Text] [Related]
18. Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis.
Egbert JR; Uliasz TF; Shuhaibar LC; Geerts A; Wunder F; Kleiman RJ; Humphrey JM; Lampe PD; Artemyev NO; Rybalkin SD; Beavo JA; Movsesian MA; Jaffe LA
Biol Reprod; 2016 May; 94(5):110. PubMed ID: 27009040
[TBL] [Abstract][Full Text] [Related]
19. Modulating cGMP to treat lung diseases.
Ghofrani HA; Grimminger F
Handb Exp Pharmacol; 2009; 191(191):469-83. PubMed ID: 19089341
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase regulation of nitric oxide signaling.
Kass DA; Takimoto E; Nagayama T; Champion HC
Cardiovasc Res; 2007 Jul; 75(2):303-14. PubMed ID: 17467673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
